Literature DB >> 25635058

Immunosilencing a highly immunogenic protein trimerization domain.

Kwinten Sliepen1, Thijs van Montfort1, Mark Melchers1, Gözde Isik1, Rogier W Sanders2.   

Abstract

Many therapeutic proteins and protein subunit vaccines contain heterologous trimerization domains, such as the widely used GCN4-based isoleucine zipper (IZ) and the T4 bacteriophage fibritin foldon (Fd) trimerization domains. We found that these domains induced potent anti-IZ or anti-Fd antibody responses in animals when fused to an HIV-1 envelope glycoprotein (Env) immunogen. To dampen IZ-induced responses, we constructed an IZ domain containing four N-linked glycans (IZN4) to shield the underlying protein surface. When fused to two different vaccine antigens, HIV-1 Env and influenza hemagglutinin (HA), IZN4 strongly reduced the antibody responses against the IZ, but did not affect the antibody titers against Env or HA. Silencing of immunogenic multimerization domains with glycans might be relevant for therapeutic proteins and protein vaccines.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  human immunodeficiency virus (HIV); humoral response; influenza; protein engineering; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25635058      PMCID: PMC4367253          DOI: 10.1074/jbc.M114.620534

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Comparing antigenicity and immunogenicity of engineered gp120.

Authors:  Suganya Selvarajah; Bridget Puffer; Ralph Pantophlet; Mansun Law; Robert W Doms; Dennis R Burton
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 2.  Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.

Authors:  Bernhard Hemmer; Olaf Stüve; Bernd Kieseier; Huub Schellekens; Hans-Peter Hartung
Journal:  Lancet Neurol       Date:  2005-07       Impact factor: 44.182

3.  Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.

Authors:  C J van der Laken; A E Voskuyl; J C Roos; M Stigter van Walsum; E R de Groot; G Wolbink; B A C Dijkmans; L A Aarden
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

4.  Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.

Authors:  Barna Dey; Marie Pancera; Krisha Svehla; Yuuei Shu; Shi-Hua Xiang; Jeffrey Vainshtein; Yuxing Li; Joseph Sodroski; Peter D Kwong; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

5.  Deceptive imprinting and immune refocusing in vaccine design.

Authors:  Gregory J Tobin; Jessie D Trujillo; Ruth V Bushnell; George Lin; A Ray Chaudhuri; Jinxue Long; Jose Barrera; Lindomar Pena; Marvin J Grubman; Peter L Nara
Journal:  Vaccine       Date:  2008-10-11       Impact factor: 3.641

6.  Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.

Authors:  Joseph P Nkolola; Hanqin Peng; Ethan C Settembre; Michael Freeman; Lauren E Grandpre; Colleen Devoy; Diana M Lynch; Annalena La Porte; Nathaniel L Simmons; Ritu Bradley; David C Montefiori; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

7.  Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.

Authors:  William C Weldon; Bao-Zhong Wang; Maria P Martin; Dimitrios G Koutsonanos; Ioanna Skountzou; Richard W Compans
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

8.  Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus.

Authors:  Chih-Jen Wei; Ling Xu; Wing-Pui Kong; Wei Shi; Kevin Canis; James Stevens; Zhi-Yong Yang; Anne Dell; Stuart M Haslam; Ian A Wilson; Gary J Nabel
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

9.  Removing T-cell epitopes with computational protein design.

Authors:  Chris King; Esteban N Garza; Ronit Mazor; Jonathan L Linehan; Ira Pastan; Marion Pepper; David Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 12.779

10.  Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Authors:  Gözde Isik; Thijs van Montfort; Nancy P Y Chung; John P Moore; Rogier W Sanders
Journal:  J Immunol       Date:  2014-04-11       Impact factor: 5.422

View more
  32 in total

1.  Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses.

Authors:  Teddy John Wohlbold; Raffael Nachbagauer; Irina Margine; Gene S Tan; Ariana Hirsh; Florian Krammer
Journal:  Vaccine       Date:  2015-05-28       Impact factor: 3.641

2.  Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles.

Authors:  Dhanu Gupta; Oscar P B Wiklander; André Görgens; Mariana Conceição; Giulia Corso; Xiuming Liang; Yiqi Seow; Sriram Balusu; Ulrika Feldin; Beklem Bostancioglu; Rim Jawad; Doste R Mamand; Yi Xin Fiona Lee; Justin Hean; Imre Mäger; Thomas C Roberts; Manuela Gustafsson; Dara K Mohammad; Helena Sork; Alexandra Backlund; Per Lundin; Antonin de Fougerolles; C I Edvard Smith; Matthew J A Wood; Roosmarijn E Vandenbroucke; Joel Z Nordin; Samir El-Andaloussi
Journal:  Nat Biomed Eng       Date:  2021-10-06       Impact factor: 25.671

3.  FRAGLER: A Fragment Recycler Application Enabling Rapid and Scalable Modular DNA Assembly.

Authors:  David Öling; Olivier Lan-Chow-Wing; Andrea Martella; Samuel Gilberto; Jordi Chi; Emily Cooper; Tora Edström; Bo Peng; Dean Sumner; Fredrik Karlsson; Petr Volkov; Carl I Webster; Robert Roth
Journal:  ACS Synth Biol       Date:  2022-07-07       Impact factor: 5.249

4.  Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.

Authors:  Hung-Chun Liao; Wan-Ling Wu; Chen-Yi Chiang; Min-Syuan Huang; Kuan-Yin Shen; Yu-Ling Huang; Suh-Chin Wu; Ching-Len Liao; Hsin-Wei Chen; Shih-Jen Liu
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

5.  A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.

Authors:  Carly M Bliss; Alec W Freyn; Tom G Caniels; Victor H Leyva-Grado; Raffael Nachbagauer; Weina Sun; Gene S Tan; Virginia L Gillespie; Meagan McMahon; Florian Krammer; Adrian V S Hill; Peter Palese; Lynda Coughlan
Journal:  Mol Ther       Date:  2022-01-07       Impact factor: 12.910

Review 6.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

7.  Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.

Authors:  Johannes S Gach; Kane J V Mara; Celia C LaBranche; Marit J van Gils; Laura E McCoy; P J Klasse; David C Montefiori; Rogier W Sanders; John P Moore; Donald N Forthal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 8.  Scratching the Surface: Resurfacing Proteins to Endow New Properties and Function.

Authors:  Alex M Chapman; Brian R McNaughton
Journal:  Cell Chem Biol       Date:  2016-05-19       Impact factor: 8.116

9.  Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer.

Authors:  Kwinten Sliepen; Thijs van Montfort; Gabriel Ozorowski; Laura K Pritchard; Max Crispin; Andrew B Ward; Rogier W Sanders
Journal:  Biomolecules       Date:  2015-10-23

10.  A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus.

Authors:  Guillaume B E Stewart-Jones; Paul V Thomas; Man Chen; Aliaksandr Druz; M Gordon Joyce; Wing-Pui Kong; Mallika Sastry; Cinque Soto; Yongping Yang; Baoshan Zhang; Lei Chen; Gwo-Yu Chuang; Ivelin S Georgiev; Jason S McLellan; Sanjay Srivatsan; Tongqing Zhou; Ulrich Baxa; John R Mascola; Barney S Graham; Peter D Kwong
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.